David A. Siegel Kiniksa Pharmaceuticals, Ltd. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Shares
6 transactions
Others Institutions Holding KNSA
# of Institutions
11Shares Held
1.89MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$37.9 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$5.06 Million2.82% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$986,7550.0% of portfolio
-
Barclays PLC London, X034.8KShares$870,6260.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$749,7000.56% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $861M
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...